Biomarkers in phase I oncology trials: Signal, noise, or expensive distraction?

被引：49

作者：

Ratain, Mark J.

Glassman, Robert H.

机构：

[1] Univ Chicago, Canc Res Ctr, Dept Med, Sect Haematol & Oncol, Chicago, IL 60637 USA

[2] Univ Chicago, Comm Clin Pharmacol & Pharmacogenom, Chicago, IL 60637 USA

[3] Merrill Lynch & Co Inc, Hlth Care Investment Banking, New York, NY USA

[4] Cornell Univ, Weill Med Coll, Div Oncol, New York, NY USA

来源：

CLINICAL CANCER RESEARCH | 2007年 / 13卷 / 22期

关键词：

D O I：

10.1158/1078-0432.CCR-07-2133

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：6545 / 6548

页数：4

共 32 条

[1] What is the right dose? The elusive optimal biologic dose in phase I clinical trials [J].

Adjei, Alex A. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (25) :4054-4055

[2] Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [J].

Atkinson, AJ ;

Colburn, WA ;

DeGruttola, VG ;

DeMets, DL ;

Downing, GJ ;

Hoth, DF ;

Oates, JA ;

Peck, CC ;

Schooley, RT ;

Spilker, BA ;

Woodcock, J ;

Zeger, SL .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :89-95

[3] Oncology's trials [J].

Booth, B ;

Glassman, R ;

Ma, P .

NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (08) :609-610

[4] Epidermal growth factor receptor overexpression: The importance of context [J].

Carbone, DP .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (23) :4268-4269

[5] Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].

Cunningham, D ;

Humblet, Y ;

Siena, S ;

Khayat, D ;

Bleiberg, H ;

Santoro, A ;

Bets, D ;

Mueser, M ;

Harstrick, A ;

Verslype, C ;

Chau, I ;

Van Cutsem, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345

[6] Sorafenib in advanced clear-cell renal-cell carcinoma [J].

Escudier, Bernard ;

Eisen, Tim ;

Stadler, Walter M. ;

Szczylik, Cezary ;

Oudard, Stephane ;

Siebels, Michael ;

Negrier, Sylvie ;

Chevreau, Christine ;

Solska, Ewa ;

Desai, Apurva A. ;

Rolland, Frederic ;

Demkow, Tomasz ;

Hutson, Thomas E. ;

Gore, Martin ;

Freeman, Scott ;

Schwartz, Brian ;

Shan, Minghua ;

Simantov, Ronit ;

Bukowski, Ronald M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :125-134

[7] Phase 2 trial of Allovectin-7 in advanced metastatic melanoma [J].

Gonzalez, Rene ;

Hutchins, Laura ;

Nemunaitis, John ;

Atkins, Michael ;

Schwarzenberger, Paul O. .

MELANOMA RESEARCH, 2006, 16 (06) :521-526

[8]

GOULART B, 2004, P ASCO, V22, pS522

[9] Trends in the use and role of biomarkers in phase I oncology trials [J].

Goulart, Bernardo H. L. ;

Clark, Jeffrey W. ;

Pien, Homer H. ;

Roberts, Thomas G. ;

Finkelstein, Stan N. ;

Chabner, Bruce A. .

CLINICAL CANCER RESEARCH, 2007, 13 (22) :6719-6726

[10] Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies [J].

Hidalgo, M ;

Siu, LL ;

Nemunaitis, J ;

Rizzo, J ;

Hammond, LA ;

Takimoto, C ;

Eckhardt, SG ;

Tolcher, A ;

Britten, CD ;

Denis, L ;

Ferrante, K ;

Von Hoff, DD ;

Silberman, S ;

Rowinsky, EK .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (13) :3267-3279

← 1 2 3 4 →